SNAP-25 Inhibitors
4 drugsAbout SNAP-25
SNAP-25 is a key protein in neurotransmitter release, functioning as a core component of the SNARE complex. This complex mediates synaptic vesicle fusion with the presynaptic membrane, leading to neurotransmitter release at nerve terminals.
Human genetic studies provide strong validation for SNAP-25 as a therapeutic target (max score 0.82). Loss-of-function variants are associated with congenital myasthenic syndromes and developmental and epileptic encephalopathy, suggesting activation may be beneficial.
SNAP-25 is targeted by 4 FDA-approved biologic drugs, including BOTOX, BOTOX COSMETIC, JEUVEAU, and DAXXIFY. These drugs are marketed by AbbVie, EVOLUS INC, and REVANCE THERAPEUTICS, INC. for CNS and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Urinary Urge Incontinence with only 2 trials.
Human Genetic Evidence Strong
SNAP-25 has strong genetic support with a maximum score of 0.82 linked to multiple diseases.
The strong genetic support increases the likelihood of clinical success for SNAP-25 targeted therapies.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in disorder of visual system, genetic, familial or congenital disease, musculoskeletal or connective tissue disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
20 totalGWAS and other genetic studies link SNAP25 to 22 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for SNAP25 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Three companies, including AbbVie, EVOLUS INC, and REVANCE THERAPEUTICS, INC., have approved drugs targeting SNAP-25.
The concentrated market suggests high entry barriers or strong patent protection for existing SNAP-25 targeting drugs.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| JEUVEAU | EVOLUS INC | 2019 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
SNAP-25 requires biologic approaches (biologic (other)), likely due to its structure or location.
The absence of small molecule or antibody drugs targeting SNAP-25 represents a potential whitespace opportunity.
Clinical Trials 428 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 71 | 58 | 7 | 6 | 89% |
| Phase 2 | 110 | 78 | 16 | 15 | 83% |
| Phase 3 | 146 | 113 | 15 | 18 | 88% |
| Phase 4 | 101 | 67 | 14 | 19 | 83% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved SNAP-25 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SNAP-25. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (1991 - 2022)
The first drug targeting SNAP-25, BOTOX, was approved in 1991, with the most recent, DAXXIFY, approved in 2022.
The 32-year span indicates a mature market, but recent approval suggests continued innovation potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 238 clinical trials targeting SNAP-25.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities